Skip to main content

Table 2 Diagnostic testing in suspected carboplatin allergy

From: Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study

Time after initial diagnosis (years)

6.5

9.5

11

11.2

Status

Prior to 2nd series of carboplatin/paclitaxel

Prior to 3rd series of carboplatin/paclitaxel

After 3 cycles carboplatin monotherapy (4th series), 0x omalizumab

After 6 cycles carboplatin (4th series) and 4x omalizumab*

Saline, diameter (mm)

0

0

0

0

Histamine, diameter (mm)

9.5

4

7.5

6

Drugs tested: diameter of wheal in mm

 Carboplatin 0.01 mg/ml

8.5

0

6

0

 Carboplatin 0.1 mg/ml

N/A

0

7

6.5

 Carboplatin 1 mg/ml

N/A

4.5

7.5

5.5

 Paclitaxel 0.001 mg/ml

0

N/A

N/A

N/A

 Paclitaxel 0.01 mg/ml

0

N/A

N/A

N/A

 Paclitaxel 0.1 mg/ml

0

N/A

N/A

N/A

 Paclitaxel 1 mg/ml

0

N/A

N/A

N/A

 Cisplatin 0.01 mg/ml

N/A

N/A

0

0

 Cisplatin 0.1 mg/ml

N/A

N/A

0

0

 Cisplatin 1 mg/ml

N/A

N/A

0

0

  1. Overview of intracutaneous testing for carboplatin and other chemotherapeutics. Positive results are shown in italics. Diameter = average of the length and width of the wheal, read 15–20 min after intracutaneous injection of the drug
  2. N/A not assessed
  3. * Skin tests were performed 8 weeks after the last omalizumab injection